{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Grade 3 Adverse Event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Grade 4 Adverse Event"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"Safety will be assessed in terms of the number of participants reporting grade 3 or higher adverse events as evaluated by Common Terminology Criteria for Adverse Events v4.0 (CTCAE).","groups":[{"description":"Patients receive Akt inhibitor MK2206 PO once weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAkt Inhibitor MK2206: 150 mg given PO","id":"OG000","title":"Treatment (Akt Inhibitor MK2206)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All patients that started protocol treatment were included in this analysis.","reportingStatus":"POSTED","timeFrame":"Time to first treatment to up to 30 days after completion of treatment","title":"Incidence of Toxicities of Akt Inhibitor MK-2206","type":"SECONDARY","unitOfMeasure":"Participants"}